Craig Adam R

President and CEO, DirectorCTI BIOPHARMA CORP (CTIC) · full profile →Form 4 · filed Jun 26, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
10
1 non-derivative · 9 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 26, 2023Tender(U)31K$9.10$286K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 26, 2023Disposed to issuer(D)900K0
Jun 26, 2023Disposed to issuer(D)1.1M0
Jun 26, 2023Disposed to issuer(D)800K0
Jun 26, 2023Disposed to issuer(D)2.3M0
Jun 26, 2023Disposed to issuer(D)470K0
Jun 26, 2023Disposed to issuer(D)600K0
Jun 26, 2023Disposed to issuer(D)475K0
Jun 26, 2023Disposed to issuer(D)1.2M0
Jun 26, 2023Disposed to issuer(D)450K0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-016480) within minutes of acceptance. Every field above traces to the original document. Verify it directly: